GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.

GSK plc American Depositary Shares (Each representing two)

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The study titled “A Phase 1/2 Open-label, Multi-center Study to Evaluat...

GSK Targets Relapsed B-Cell Lymphoma With New Early-Stage Trial

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK has reported results for ZEAL-1L, a Phase 3 trial officially titled...

GSK’s ZEAL-1L Lung Cancer Trial Delivers Mixed Readout With Limited Upside for Niraparib

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK and Spero Therapeutics have secured US FDA approval for Utebzi (tebipenem pivoxil)...

GSK wins first US approval for oral carbapenem to treat complicated UTIs

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK has launched a first-in-human trial of its new antibody GSK4425689A...

GSK Opens New Front in Malaria Prevention With First-in-Human Antibody Trial

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline, with a price target of $70.00. According to TipR...

TD Cowen Keeps Their Hold Rating on GlaxoSmithKline (GSK)

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1, Randomized, Placebo-Controlled, Double-Bl...

GSK Advances New COPD Candidate With Completed Phase 1 Ethnic-Sensitivity Study

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK disclosed that several senior executives, including President Europe Lynn Baxter an...

GSK Executives Acquire Shares Under Company Reward Plan

In a report released today, from Intron Health upgraded GlaxoSmithKline to a Hold, with a price target of p2,000.00. In addition to Intron Health, ...

GlaxoSmithKline (GSK) was upgraded to a Hold Rating at Intron Health

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK disclosed that Maya Martinez-Davis, its President of U.S. operations, acquired noti...

GSK US President Acquires Notional ADS Under Executive Savings Plan

GlaxoSmithKline ( ($GB:GSK) ) has issued an update. GSK has announced that non-executive director Dr Hal Barron has been appointed an independent d...

GSK Director Hal Barron Takes Governance Role at Quantinuum

In a report released today, Zain Ebrahim from J.P. Morgan maintained a Sell rating on GlaxoSmithKline, with a price target of £17.00. According to ...

J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)

UBS analyst Matthew Weston maintained a Hold rating on GlaxoSmithKline today and set a price target of £19.40. According to TipRanks, Weston is a 4...

UBS Remains a Hold on GlaxoSmithKline (GSK)

Barclays analyst James Gordon CFA maintained a Sell rating on GlaxoSmithKline today and set a price target of £18.00. According to TipRanks, Gordon...

GlaxoSmithKline (GSK) Gets a Sell from Barclays

GlaxoSmithKline ($GSK) is reportedly in talks to acquire cancer drugmaker Nuvalent ($NUVL). According to The Financial Times, citing people familia...

Why GSK May Acquire Nuvalent — Report Points to $9B+ Deal Talks

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline today and set a price target of £19.00. Papadakis covers the H...

Deutsche Bank  Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GlaxoSmithKline (GB:GSK) and C4 Therapeutics (CCCC). GlaxoSmithKl...

Analysts Conflicted on These Healthcare Names: GlaxoSmithKline (GB:GSK) and C4 Therapeutics (CCCC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GlaxoSmithKline (GSK) and Savara (SVRA). GlaxoSmithKline (GSK) In...

Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GSK) and Savara (SVRA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Staar Surgical (STAA), Cogent Biosciences (COGT) and...

Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Cogent Biosciences (COGT) and GlaxoSmithKline (GSK)

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK’s latest update covers a Phase 2a trial titled “A Phase 2a Randomiz...

GSK’s mRNA Flu Vaccine Trial Reaches Key Phase 2 Milestone, Eyeing Next-Gen Seasonal Market

J.P. Morgan analyst Zain Ebrahim maintained a Sell rating on GlaxoSmithKline today and set a price target of £17.00. According to TipRanks, Ebrahim...

An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK reported pivotal phase III data showing its investigational antisense oligonucle...

GSK’s bepirovirsen delivers landmark functional cure rates in chronic hepatitis B phase III trials

In a report released on May 26, Nicolas Pauillac from Kepler Capital upgraded GlaxoSmithKline to a Buy, with a price target of p2,516.00. According...

Positive Report for GlaxoSmithKline (GSK) from Kepler Capital

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline (through ViiV Healthcare) has completed a Phase 3b stud...

GSK’s Long-Acting HIV Study Nears the Finish Line: What Investors Should Watch

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK plc disclosed that Maya Martinez-Davis, its President for the US, acquired notiona...

GSK Discloses Notional ADS Purchase by US President Martinez-Davis

Deutsche Bank analyst Emmanuel Papadakis reiterated a Hold rating on GlaxoSmithKline today and set a price target of p1,900.00. Papadakis covers th...

GlaxoSmithKline (GSK) Receives a Hold from Deutsche Bank

In a report released today, Michael Leuchten from Jefferies maintained a Buy rating on GlaxoSmithKline, with a price target of £25.00. According to...

GlaxoSmithKline (GSK) Receives a Buy from Jefferies

Barclays analyst James Gordon CFA maintained a Sell rating on GlaxoSmithKline today and set a price target of £18.00. Gordon CFA covers the Healthc...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GSK	$50.67	-2.84%	4.22M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GSK	$50.67	-2.8%	4.22M
3
4
5
6

GSK

GSK

Recent News for GSK

Get GSK plc American Depositary Shares (Each representing two) Data in Excel

Get GSK plc American Depositary Shares (Each representing two) Data in Excel